Fresenius SE & Co KGaA - Company Profile
Powered by 
All the data and insights you need on Fresenius SE & Co KGaA in one report.
$295
- Save hours of research time and resources with
our up-to-date Fresenius SE & Co KGaA Strategy Report
- Understand Fresenius SE & Co KGaA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Fresenius SE & Co KGaA (Fresenius) focuses on hospital operations. It provides products and services for dialysis, hospitals, and outpatient medical care. It is one of the world's largest integrated providers of products and services for dialysis in patients with chronic kidney failure.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Fresenius’s R&D efforts focus on core competencies in the areas of dialysis, biosimilars, infusion and nutrition therapies, generic IV drugs and medical devices In the area of transfusion technology, the company’s research and development activities focus on developing products for use in cell therapy. It specializes in developing products for automatically washing and concentrating cell concentrates, which are utilized in treatments like CAR T-cell therapy. In the area of generic IV drugs, the company’s research and development activities focus on developing complex formulations like an emulsion solution that has already been approved as a first-to-file abbreviated new drug application in the US and peptide formulations that can be administered using an autoinjector and other methods. In the field of medical devices, the company prioritizes the development of new products as well as the expansion of its existing portfolio. Digitalization is a significant aspect of the medical industry, requiring devices to be updated to fit into the IT systems of hospitals, blood donation centers, and plasma centers. The company is committed to bringing more therapeutic solutions to more patients in the biopharmaceutical space. In FY2022, Fresenius spent EUR852 million on R&D, which as a percentage of revenue stood at 2.1%, and grew 4.2% YoY. It has major R&D facilities in Europe, the US, and India.
Business Segments
Overview
Owns and operates Helios hospitals in Germany and Quironsalud hospitals in Latin America and Spain. Envisages considerable investments to expand and enhance its hospitals. Includes Helios Germany, Helios Spain and the Eugin Group.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Manages projects and offers services for hospitals and other health care facilities across the world. The company completed more than 960 projects in 95 countries. Major services include consulting, project development, planning, turnkey construction, maintenance, administrative management and operational management. Consists of two reporting units: Project business and Service business. Envisages considerable investment to expand and enhance its product portfolio.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Provides medicines and technologies for infusion, transfusion and clinical nutrition. It also develops biosimilars focusing on oncology and autoimmune diseases. Major infusion therapy products include intravenously administered generic drugs (IV drugs) and infusion pumps. Major clinical nutrition products include enteral nutrition and parenteral nutrition. Major transfusion technology products include autotransfusion devices, cell separators (apheresis systems), blood bag and filter systems and related blood processing equipment. Envisages considerable investment to expand and enhance its portfolio.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Offers products and services for patients with chronic kidney failure. It also offers non-dialysis services in the area of Care Coordination. Major health care products include hemodialysis machines, peritoneal dialysis cyclers, dialyzers, peritoneal dialysis solutions, hemodialysis concentrates, granulates, bloodlines, systems for water treatment, renal pharmaceuticals, other equipment and medical devices, acute cardiopulmonary products and apheresis products. Major health care services include end-stage renal disease-related treatments, end-stage renal disease-related laboratory testing services, acute dialysis services, pharmacy services, vascular, cardiovascular and endovascular specialty services, ambulatory surgery center services, value and risk based arrangements, urgent care services, physician nephrology services and ambulant treatment services.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Target Markets
Japan, Australia, New Zealand, Korea, China, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Target Markets
France, Italy, Germany, Spain, the UK, Switzerland, Benelux, Nordic, Central and Eastern Europe.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward